Kairos Pharma, Ltd.
KAPAKairos Pharma, Ltd. (KAPA) is a biotechnology company focused on the development of innovative pharmaceutical therapies. The company specializes in research and development aimed at addressing unmet medical needs through novel drug candidates and delivery systems in various therapeutic areas.
Company News
The Schall Law Firm is investigating Kairos Pharma, Ltd. on behalf of investors for potential securities law violations, including allegations of false or misleading statements and failure to disclose material information. Shareholders who suffered losses are encouraged to participate in the investigation.
Kairos Pharma, a clinical-stage biopharmaceutical company, has closed its $6.2 million initial public offering. The company plans to use the proceeds to fund its Phase 1 and Phase 2 trials for its lead product candidate ENV 105 and advance its preclinical candidate KROS 101.
